Sangui Biotech International, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020
May 14, 2020 at 02:50 pm EDT
Share
Sangui Biotech International, Inc. announced earnings results for the third quarter ended March 31, 2020. For the third quarter, the company announced operating loss was USD 37,455 compared to USD 74,150 a year ago. Net loss was USD 26,696 compared to USD 66,413 a year ago. For the nine months, operating loss was USD 129,886 compared to USD 227,785 a year ago. Net loss was USD 123,428 compared to USD 212,732 a year ago.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
